Concept Life Sciences expands expertise with key appointments to Scientific Advisory Board and investments to strengthen integrated drug discovery capabilities
- Appointments come as the business invests a six-figure sum into advanced technology and systems -
CHAPEL-EN-LE-FRITH, United Kingdom, April 15, 2025 (GLOBE NEWSWIRE) -- Concept Life Sciences (CLS), a leading integrated drug discovery, development, and manufacturing organisation backed by Limerston Capital, today announced key strategic appointments and advancements to further strengthen its services for the global pharmaceutical and biotechnology sectors.
CLS is pleased to welcome Professor Luke O'Neill, and Dr. Shane Liddelow to its Scientific Advisory Board (SAB), while Dr. Ian Waddell, who joined the Board of Directors last year, continues to provide invaluable leadership.
The appointments to the SAB reinforce CLS's position as a leading partner for innovative drug discovery solutions. Professor O'Neill and Dr. Liddelow bring a wealth of expertise across immunology and neuroscience, respectively, enhancing CLS's ability to meet the evolving needs of the global life sciences industry.
CLS has made major advancements in automated solid-phase peptide synthesis (SPPS) capabilities. Combined with in-house peptide experts, this enables it to accelerate client projects requiring challenging custom peptide synthesis.
In addition, CLS has made a significant investment, amounting to a five-figure sum in GBP, to enhance its capabilities in Automated ADME (Absorption, Distribution, Metabolism, Excretion) systems and the purchase of a Supercritical Fluid Chromatography purification instrument. This strategic investment drives industry-leading assay turnaround times with no minimum volume requirement and strengthens CLS's ability to provide high-quality, tailored services, particularly for complex drug discovery projects.
These investments further solidify CLS's standing as a key partner to pharmaceutical and biotech companies, providing comprehensive drug discovery services from early-stage research through to clinical trials.
The news follows CLS's acquisition of Charnwood Discovery which completed at the end of 2024 and further enhances the company's integrated drug discovery offer. This underlines the business's growth strategy, demonstrating its ambitions and further strengthening its ability to accelerate drug candidates to clinic with high success rates and across different modalities.
About the Scientific Advisory Board Members:
Professor Luke O'Neill, FRS, is an immunologist and Chair of Biochemistry at Trinity College Dublin. With over 460 peer-reviewed publications, his research focuses on inflammation, innate immunity, and immunometabolism, providing deep expertise in areas critical to drug discovery. Professor O'Neill has received over 110,000 citations and has an h-index of 160, underscoring his significant contributions to the field.
Dr. Shane Liddelow is an Associate Professor at NYU Langone Medical Center, specialising in neurodegenerative diseases. His research into the role of astrocytes in diseases like Alzheimer's and Parkinson's offers valuable insight for neurodegenerative drug discovery. Dr. Liddelow has garnered over 30,000 citations and holds an h-index of 52, which reflects his important research in neurodegeneration.
Dr. Ian Waddell, appointed to the CLS Board of Directors last year, has more than 27 years of experience across all stages of drug discovery. His expertise spans cardiovascular and oncology disease areas, and his leadership in the field has been instrumental in advancing drug development programs.
Ben Cliff, CEO of Concept Life Sciences, commented: 'The addition of Luke, Shane, and Ian to our advisory and leadership teams is an exciting step in enhancing our scientific expertise and global service offering.
'As we strive to stay at the forefront of research and innovation, our continued investments in technology and talent, including our protein production capabilities and cutting-edge purification systems, reinforce our commitment to delivering high-quality, integrated services to the global biopharmaceutical community.'
Dr. Ian Waddell, added: 'My role with the Scientific Advisory Board allows me to contribute from a strategic leadership perspective, ensuring that our scientific initiatives align with the company's broader goals. The expertise of Professor O'Neill and Dr. Liddelow, combined with continued investments in cutting-edge technologies, reinforces CLS's commitment to advancing drug discovery and I look forward to collaborating with such a distinguished panel to drive impactful outcomes for clients and the wider industry.'
About Concept Life Sciences
Founded in 1999, Concept Life Sciences is a leading contract research organisation (CRO), primarily serving the pharmaceutical and life science research and development market. Offering world-class and technologically advanced, fully integrated drug discovery and development services for all drug modalities including small molecules, biologics, cell & gene therapies and beyond with clients in the global pharmaceutical and biotechnology space ranging from blue chip to virtual biotech.
CLS has an impressive quantitative track record, with an average of just 32 months to advance a drug from concept to clinic, well ahead of the industry average of 60 months. The company has successfully helped accelerate five drugs to market, 28 candidates to the clinic, and 44 candidates to the pre-clinical stage. This remarkable success underscores CLS's ability to deliver high-quality, fast-tracked results and reinforce the value it provides to its customers. With a stringent focus on quality, CLS offers a broad and deep expertise, from drug discovery through early-stage development to multi-kilogram API manufacturing for phase 1 clinical trials. The company has around 230 employees and operates out of four state-of-the-art UK facilities.
www.conceptlifesciences.com
About Limerston Capital
Founded in 2015 by James Paget, João Rosa and Martim Avillez, London based Limerston Capital pursues control investments in UK mid-market companies and seeks to create value through the firm's buy-and-build and operationally focused model. The firm targets businesses with EBITDA of between £5 million and £15 million that have a solid value proposition, but have potential for operational improvements, have mispriced underlying returns on capital and provide opportunities for strategic repositioning via consolidation.
www.limerstoncap.com
ContactsConcept Life SciencesBen CliffEmail: cls-info@conceptlifesciences.comScius Communications Katja Stout+44 778 943 5990katja@sciuscommunications.com Daniel Gooch+44 7747 875479daniel@sciuscommunications.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Global Uranium Corp. Announces LIFE Offering for up to C$1,500,000
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 10, 2025 (GLOBE NEWSWIRE) -- Global Uranium Corp. (CSE: GURN | FRA: Q3J) (the 'Company') is pleased to announce that it intends to complete a non-brokered private placement financing (the 'Offering') of a minimum of 1,666,666 units of the Company (each, a 'Unit') and a maximum of 10,000,000 Units, at a price of C$0.15 per Unit, for gross minimum proceeds of C$250,000 and gross maximum proceeds of C$1,500,000. Each Unit shall be comprised of one common share in the capital of the Company (each, a 'Share') and one Share purchase warrant ('Warrant'), with each Warrant entitling the holder to purchase one Share at a price of C$0.20 for a period of 24 months from Closing (as defined herein). Closing of the Offering is anticipated to occur on or about July 25, 2025 ('Closing'), subject to the satisfaction of certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. The net proceeds of the Offering are intended to be used for exploration activities, for general administrative expenditures, and for general working capital purposes. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions ('NI 45-106'), the securities issuable under the Offering will be offered for sale to purchasers resident in all of the provinces of Canada (except Quebec) pursuant to the listed issuer financing exemption under Part 5A.2 of NI 45-106 (the 'LIFE Exemption'). As such, the securities issued to subscribers will not be subject to resale restrictions in accordance with applicable Canadian securities laws. There is an offering document dated June 10, 2025 related to the Offering that can be accessed under the Company's profile at and on the Company's website at This offering document contains additional detail regarding the Offering, including additional detail regarding the expected use of proceeds therefrom. Prospective investors in the Offering should read this offering document before making an investment decision. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any United States state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any available exemption from the registration requirements of the U.S. Securities Act and applicable United States state securities laws. This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. ABOUT GLOBAL URANIUM CORP. Global Uranium Corp. focuses on exploring and developing uranium assets primarily in North America. The Company currently holds key uranium projects: the Wing Lake Property in the Mudjatik Domain of Northern Saskatchewan, Canada; the Northwest Athabasca Joint Venture with Forum Energy Metals Corp. and NexGen Energy Ltd. in the Northwest Athabasca region of Saskatchewan, Canada; the Astro Uranium Project with Cosa Resources Corp in the eastern Athabasca Basin, Saskatchewan; and the Great Divide Basin District Projects, the Gas Hills District Projects, and the Copper Mountain District Projects in Wyoming, USA. ON BEHALF OF THE BOARD OF DIRECTORSUngad ChaddaCEO 587-330-0045info@ FORWARD-LOOKING STATEMENTS Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words 'could', 'intend', 'expect', 'believe', 'will', 'projected', 'estimated' and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. In particular, this press release contains forward-looking information relating to, among other things, the Offering, including the total anticipated proceeds, the expected use of proceeds, and the closing (including the proposed closing date) of the Offering. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information, including the assumption that the Company will close the Offering on the timeline anticipated, will raise the anticipated amount of gross proceeds from the Offering and will use the proceeds of the Offering as anticipated. Those assumptions and factors are based on information currently available to the Company. Although such statements are based on reasonable assumptions of the Company's management, there can be no assurance that any conclusions or forecasts will prove to be accurate. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include: the risk that the Offering does not close on the timeline expected, or at all; the risk that the Company raises less than the anticipated amount of gross proceeds from the Offering; the risk that the Company does not use the proceeds from the Offering as currently expected; risks inherent in the exploration and development of mineral deposits, including risks relating to receiving requisite permits and approvals, changes in project parameters or delays as plans continue to be redefined, that mineral exploration is inherently uncertain and that the results of mineral exploration may not be indicative of the actual geology or mineralization of a project; that mineral exploration may be unsuccessful or fail to achieve the results anticipated by the Company; operational risks; regulatory risks, including risks relating to the acquisition of the necessary licenses and permits; financing, capitalization and liquidity risks; title and environmental risks; and risks relating to the failure to receive all requisite regulatory approvals. The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein. The Canadian Securities Exchange has not reviewed, approved, or disapproved the contents of this press release.Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
ColonBroom GLP-1 Booster Website Updated to Highlight Daily Supplement for Metabolic Health
New website update showcases natural GLP-1 support supplement designed to curb cravings, support metabolism, and promote healthy weight management SAN FRANCISCO, June 10, 2025 (GLOBE NEWSWIRE) -- ColonBroom, a U.S.-based wellness brand, has announced a new update to its official website to highlight the launch of ColonBroom GLP-1 Booster—a daily supplement formulated to support metabolic function, appetite regulation, and overall weight wellness. Now available across the United States, the product offers a natural, lifestyle-friendly solution backed by science-supported ingredients. According to the official product website ( ColonBroom GLP-1 Booster is designed to work alongside the body's internal systems by promoting satiety, curbing cravings, and supporting blood sugar balance. The formula targets key wellness goals like reducing excess visceral fat and helping users manage weight more effectively without relying on restrictive diets or intense routines. 'ColonBroom GLP-1 Booster reflects our mission to simplify wellness with natural tools that align with modern lifestyles,' said a company spokesperson. 'This formula is designed with purpose—combining evidence-backed ingredients for those seeking real metabolic support.' The formulation includes Berberine, Chromium Picolinate, 5-HTP, Saffron Extract, and Bupleurum Root Extract—ingredients selected for their known roles in supporting GLP-1 activity, blood sugar balance, mood regulation, and fat metabolism. ColonBroom confirms that all supplements are manufactured in facilities that adhere to rigorous quality and safety protocols. The brand offers a satisfaction guarantee for new customers and invites visitors to explore ingredient insights, customer FAQs, and personalized quiz recommendations directly on the website. About ColonBroom ColonBroom is a San Francisco-based wellness brand dedicated to creating clean, effective, and easy-to-use daily supplements. With a focus on transparency and science-backed simplicity, ColonBroom empowers adults to take proactive steps toward digestive and metabolic wellness. Product and Contact Information Brand: ColonBroomWebsite: hello@ (Order Support): 1-888-505-0855Mailing Address: 505 Montgomery Street, 10th & 11th Floors, San Francisco, California, 94111, USA Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement. CONTACT: Email: hello@ Phone (Order Support): 1-888-505-0855Sign in to access your portfolio
Business Upturn
an hour ago
- Business Upturn
ROOH Officially Opens in Toronto With Focus on Health-Conscious Indian Cuisine
ROOH has officially launched in downtown Toronto, offering a health-focused Indian dining experience centered on nutrition, sustainability, and regional flavors. The new restaurant builds on Bar Goa's model by applying research-based cooking and transparent sourcing to modern fine dining. Photo Courtesy of ROOH TORONTO, June 10, 2025 (GLOBE NEWSWIRE) — ROOH has opened its doors at 633 College Street in Toronto, offering a menu centered on sustainability, nutrition, and regionally inspired Indian flavors. The restaurant represents the second concept from the team behind Bar Goa, recognized in the 2024 Michelin Guide. ROOH offers a distinct alternative to traditional Indian dining by combining public health principles with acceptable dining practices. The venue features a seasonally adjusted menu built around transparent sourcing and scientific cooking practices to preserve nutrients and support long-term wellness. The kitchen team follows structured methods informed by behavioral science and nutritional research. Staff receive ingredient sourcing, food science, and guest communication training, supporting the restaurant's broader mission to connect hospitality with public health goals. ROOH expands on Bar Goa's health-forward model by drawing from culinary traditions across India. The menu features seasonal vegetables, fermented ingredients, and spice blends supported by nutrition studies. The team develops dishes by drawing on regional culinary research and partnering with local ingredient suppliers. 'We apply food science alongside tradition to raise the profile of regional Indian cuisine,' says founder Dr. Jayadeep Patra. 'This method offers a new take that fits today's changing dining scene.' The restaurant's model responds to increasing demand for meals combining rich flavor and wellness alignment. ROOH's operational structure reflects a long-term vision to integrate evidence-based practices into modern dining experiences. Together with its sister restaurant, Bar Goa, ROOH continues to evolve a food philosophy rooted in sustainability, science, and culturally grounded cuisine. About ROOH and Bar Goa ROOH and Bar Goa are Indian fine-dining restaurants based in Toronto. They were built on the work of public health scientist and restaurateur Dr. Jayadeep Patra. The Michelin Guide recognized Bar Goa in 2024 for its health-conscious coastal Indian cuisine. ROOH builds on this model by offering seasonal, regional Indian dishes shaped by nutritional research and sustainability practices. Both restaurants highlight transparency, ingredient integrity, and a hospitality approach informed by science. Contact information: Contact Person's Name: Dr. Jayadeep Patra Organization / Company: ROOH and Bar Goa Company website: | Contact Email Address: [email protected] City, Province, Country: 633 College St, Toronto, Ontario, Canada A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
